APVO - Aptevo initiates expansion phase of APVO436 acute myeloid leukemia study

Aptevo Therapeutics (APVO) has initiated the expansion phase of the company's APVO436 study, in adult patients with acute myeloid leukemia ((AML)), with a multi-center, multi-arm trial using the active recommended dose.The active recommended dose was identified in the dose escalation phase ((Part 1)) of the study.During Part 1, APVO436 exhibited a manageable side effect profile, encouraging single agent activity and a promising benefit to risk profile in relapsed AML patients, the company said.The dose expansion phase ((Part 2)), has been designed to further evaluate the tolerability and clinical impact potential of APVO436.The goal of the expansion phase is to evaluate the safety and tolerability of APVO436 at the recommended Phase 2 dose level, when it is used as an adjunct to the standard of care and to obtain a preliminary assessment of anti-leukemia activity.The company expects to post interim data from Part 2 of the trial later this year.Aptevo had shared

For further details see:

Aptevo initiates expansion phase of APVO436 acute myeloid leukemia study